TY - JOUR
T1 - The clone wars - revenge of the metastatic rogue state
T2 - The sarcoma paradigm
AU - Spraker, Holly L.
AU - Price, Shawn L.
AU - Chaturvedi, Aashi
AU - Schiffman, Joshua D.
AU - Jones, Kevin B.
AU - Lessnick, Stephen L.
AU - Beckerle, Mary
AU - Randall, R
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Ewing sarcoma (ES) is the second most common bone tumor affecting primarily adolescents and young adults. Despite recent advances in biological understanding, intensification of chemotherapeutic treatments, and progress in local control with surgery and/or radiation therapy, patients with metastatic or recurrent ES continue to have a dismal prognosis with less than 20% overall survival. All ES is likely metastatic at diagnosis although our methods of detection and classification may not account for this. Progressive disease may arise via a combination of: (1) selection of chemotherapy-resistant clones in primary tumor, (2) signaling from bone or lung microenvironments that may attract tumor cells to distant locations, and/or (3) genetic changes within the ES cells themselves due to DNA-damaging chemotherapeutic agents or other "hits." These possibilities and the evidence base to support them are explored.
AB - Ewing sarcoma (ES) is the second most common bone tumor affecting primarily adolescents and young adults. Despite recent advances in biological understanding, intensification of chemotherapeutic treatments, and progress in local control with surgery and/or radiation therapy, patients with metastatic or recurrent ES continue to have a dismal prognosis with less than 20% overall survival. All ES is likely metastatic at diagnosis although our methods of detection and classification may not account for this. Progressive disease may arise via a combination of: (1) selection of chemotherapy-resistant clones in primary tumor, (2) signaling from bone or lung microenvironments that may attract tumor cells to distant locations, and/or (3) genetic changes within the ES cells themselves due to DNA-damaging chemotherapeutic agents or other "hits." These possibilities and the evidence base to support them are explored.
KW - Ewing sarcoma
KW - Metastatic
UR - http://www.scopus.com/inward/record.url?scp=84870965277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870965277&partnerID=8YFLogxK
U2 - 10.3389/fonc.2012.00002
DO - 10.3389/fonc.2012.00002
M3 - Comment/debate
AN - SCOPUS:84870965277
VL - 2
JO - Frontiers in Oncology
JF - Frontiers in Oncology
SN - 2234-943X
IS - JAN
M1 - 00002
ER -